Drug therapies in severe asthma – the era of stratified medicine

Authors: Kathy J Hetherington and Liam G Heaney

Difficult-to-treat asthma affects up to 20% of patients with asthma and is associated with significant healthcare cost. It is an umbrella term that defines a heterogeneous clinical problem including incorrect diagnosis, comorbid conditions and treatment non-adherence; when these are effectively addressed, good symptom control is frequently achieved. However, in 3–5% of adults with difficult-to-treat asthma, the problem is severe disease that is unresponsive to currently available treatments. Current treatment guidelines advise the ‘stepwise’ increase of corticosteroids, but it is now recognised that many aspects of asthma are not corticosteroid responsive, and that this ‘one size fits all’ approach does not deliver clinical benefit in many patients and can also lead to side effects. The future of management of severe asthma will involve optimisation with currently available treatments, particularly corticosteroids, including addressing non-adherence and defining an ‘optimised’ corticosteroid dose, allied with the use of ‘add-on’ target-specific novel treatments. This review examines the current status of novel treatments and research efforts to identify novel targets in the era of stratified medicines in severe asthma.

KEYWORDS: Severe asthma, stratified medicine, personalised medicine

Introduction

Up to 20% of patients with asthma do not achieve an acceptable level of control, despite being prescribed high-dose anti-inflammatory and bronchodilator therapy, and are referred to as having ‘difficult-to-treat asthma’ or ‘difficult asthma’. Difficult asthma is not a diagnosis, but is an umbrella term to describe a clinical problem that requires careful assessment. In many cases, after detailed systematic evaluation, a coexistent problem is identified (see Box 1), either alone (misdiagnosis) or together with mild/moderate asthma, and when this is effectively managed, symptoms can be controlled.

Box 1. Coexistent conditions that can cause persistent ‘asthma-like’ symptoms, from case series of difficult asthma. Reproduced with permission.

> Dysfunctional breathlessness
> Vocal cord dysfunction
> Hyperventilation with panic attacks
> Obesity/physical deconditioning
> Chronic obstructive pulmonary disease
> Bronchiolitis obliterans
> Cardiac disease – congestive heart failure, cardiomyopathy
> Pulmonary vascular disease
> Bronchiectasis/cystic fibrosis
> Immunodeficiency
> Hypersensitivity pneumonitis
> Allergic bronchopulmonary aspergillosis
> Hypereosinophilic syndromes/Churg–Strauss syndrome
> Acquired tracheobronchomalacia

However, within this group of patients with difficult asthma, some patients will have severe refractory asthma, where persistent symptoms and exacerbations are due to asthma that cannot be controlled with currently available treatments. Current asthma international treatment guidelines advocate a ‘one size fits all’ approach to treating asthma with progressive escalation of treatment, particularly corticosteroid treatment, to try to achieve asthma control. Indeed, the current definition of severe asthma mandates escalation to high-dose treatment (high-dose inhaled corticosteroids plus second controller for the previous year or systemic corticosteroids ≥50% of the previous year), which either maintains asthma control or fails to achieve control. Uncontrolled asthma is defined as persisting asthma symptoms, frequent severe exacerbations requiring at least two bursts of systemic corticosteroids (or a hospitalisation) in the previous year, or persistent airflow limitation. Controlled asthma that worsens on tapering of high-dose corticosteroid treatment or use of additional biological therapy also fits into the category of severe disease. It is important to stress that a diagnosis of severe refractory asthma is applied only after detailed systematic
multidisciplinary assessment for patients with asthma in whom alternative diagnoses have been excluded, adherence with treatment has been checked, comorbidities have been treated, and trigger factors have been removed (where this is possible). With the advent of multiple new therapeutic options for severe asthma over the next few years (discussed below), it is more critical than ever to get the diagnosis and these core basic issues correct to avoid inappropriate targeting of these novel and potentially expensive therapies. The specialist commissioning of severe asthma services currently being advanced by NHS England endorses this type of approach in regional difficult asthma centres, and aims to deliver systematic assessment and specialist care in tertiary respiratory centres providing multidisciplinary diagnostic, assessment and treatment service for individuals with severe asthma. It also states that a key role is “…to act as gatekeepers for the use of bronchial thermoplasty and omalizumab, as well as other high cost novel biological agents currently in development, to prevent inappropriate use, unnecessary risk to patients and spiralling costs to the NHS.”

A clear example of where this systematic approach is critical is addressing the challenge of non-adherence with maintenance inhaled steroid treatment, which is prevalent in patients presenting with difficult asthma. It is poorly identified in routine clinical practice, leading to poor healthcare outcome and death, and can result in patients being inappropriately labelled as having severe disease, with the potential for inappropriate escalation to systemic corticosteroids or biological therapies. In patients with difficult asthma, sputum eosinophilia has been shown to be significantly higher than in patients with severe disease who are adherent with high-dose inhaled steroid treatment. Patients with persistent airway eosinophilia have frequent exacerbations and often have peripheral blood eosinophilia, which are likely to be the core criteria for access to the novel biological therapies targeting interleukin (IL)-5. Given the poor clinical outcome, inappropriate escalation to these novel therapies seems almost inevitable unless non-adherence is identified more efficiently in specialist clinical services. Recent ‘biomarker-based’ assessments of corticosteroid response may identify patients who should achieve good asthma control with better adherence to standard treatment. An advantage of this type of testing is that it can also identify ‘non-intentional’ non-adherence, where despite efforts to take inhalers and good prescription filling, actual adherence is poor (poor inhaler technique, poor recall of instruction, low comprehension etc.). This testing is relatively simple and can be delivered using remote technologies, and will be explored as part of the Medical Research Council-funded Refractory Asthma Stratification Programme (RASP-UK). A key challenge remains how to manage non-adherence effectively in this patient group, but the starting point is identifying that non-adherence is the clinical problem in a patient who should respond well to inhaled steroid treatment.

A number of comorbidities are commonly reported in a population with severe asthma (Box 2), and management guidelines advocate the clinical management of these comorbidities. However, the evidence that managing these comorbidities has a major clinical impact on asthma outcome in this population is limited. For example, despite a substantial body of literature discussing the relationship between gastro-oesophageal reflux and asthma, causality has not been established, and although common in all severities of asthma including difficult asthma, the results of antacid therapy have been disappointing. This may be because non-acid reflux is still occurring or because the presence of gastro-oesophageal reflux has little impact on underlying asthma. Gastro-oesophageal reflux can be effectively surgically treated with fundoplication and efficacy has been suggested in asthma. However, a ‘sham-controlled’ fundoplication study has never been performed and this type of study has been useful in questioning established surgical practice in other disease areas. Similarly, the precise link between obesity and severe asthma remains unclear; however, discrete obese phenotypes still occurring or because the presence of gastro-oesophageal reflux remain unclear. As can be seen from these examples, a challenge for the future will be to tease out association from ‘cause and effect’ for all of the commonly reported morbidities in severe asthma, which will allow more evidence-based targeting of interventions, including invasive surgical procedures, in this patient group.

Patients on high-dose corticosteroid treatment, particularly where it includes recurrent systemic exposure, also develop well-recognised side effects including osteoporosis, diabetes mellitus, hypertension, cataracts, psychological disturbance and cushingoid features. Previous studies of immunosuppressants have included small numbers of patients in randomised controlled trials and have concluded that, although there may be small steroid-sparing effects, the side-effect profile does not justify their use. Novel therapies targeting corticosteroid-responsive biology are likely to reduce systemic corticosteroid exposure more effectively than immunosuppressants in severe asthma. Allied with a strategy to prevent inappropriate escalation of corticosteroid treatment, 

<table>
<thead>
<tr>
<th>Box 2. Comorbidities commonly reported in severe asthma.</th>
</tr>
</thead>
<tbody>
<tr>
<td>&gt; Rhinosinusitis/(adults) nasal polyps</td>
</tr>
<tr>
<td>&gt; Psychological factors: personality trait, symptom perception, anxiety, depression</td>
</tr>
<tr>
<td>&gt; Vocal cord dysfunction</td>
</tr>
<tr>
<td>&gt; Obesity and physical deconditioning</td>
</tr>
<tr>
<td>&gt; Smoking/smoking-related disease</td>
</tr>
<tr>
<td>&gt; Obstructive sleep apnoea</td>
</tr>
<tr>
<td>&gt; Hyperventilation syndrome</td>
</tr>
<tr>
<td>&gt; Hormonal influences: premenstrual, menstrual, menopause, thyroid disorders</td>
</tr>
<tr>
<td>&gt; Gastro-oesophageal reflux disease</td>
</tr>
<tr>
<td>&gt; Drugs including aspirin, non-steroidal anti-inflammatory drugs, β-adrnergic blockers, angiotensin-converting enzyme inhibitors</td>
</tr>
</tbody>
</table>
this would deliver a step change in the iatrogenic morbidity in this group. However, in one recent study with mepolizumab, a monoclonal antibody against IL-5, only a modest reduction in the maintenance dose of oral glucocorticoids was seen (median-dose prednisone in the mepolizumab group reduced from 10.0 mg to 3.1 mg per day, compared with a reduction from 12.5 mg per day to 10.0 mg per day in the placebo arm) and few patients managed to withdraw oral steroids completely. However, there was also a 32% reduction in exacerbations in the mepolizumab-treated group, suggesting further reduction in rescue steroid exposure. It remains to be seen whether the ‘steroid-sparing’ effect is clinically meaningful to patients with a reduction in steroid-induced side effects; however, the side-effect profile of this agent and other biological therapies seems very favourable. It also remains to be seen whether the benefits to patients will mitigate the costs of treatment with mepolizumab.

Recent data in patients with both mild and severe asthma suggest that there is evidence of significant disease heterogeneity,25-29 and examining gene signatures in well-characterised cohorts of patients with severe asthma has demonstrated that between 25% and 50% of patients have a prototypic type-2 cytokine gene signature, so-called ‘T2-high’ disease (with elevated IL-4, -5 and -13 and airway eosinophilia, despite adherence with high-dose corticosteroid treatment). In patients with severe asthma with no evidence of T2 inflammation (‘T2-low asthma’), it is likely that their corticosteroid dose has been escalated inappropriately to try to manage persistent symptoms that are not corticosteroid responsive. Given the evidence that corticosteroid responsiveness is confined to T2-high disease,26,30,31 a key challenge for the management of severe asthma in the future is to develop objective tests and validated management algorithms not only to initiate corticosteroid treatment, but also to allow clinicians to determine that additional corticosteroid treatment will not produce any further clinical response. Moving away from the currently advocated symptoms-driven escalation of corticosteroid treatment will be a major component of delivering ‘personalised treatment’ in severe asthma in the future, and will facilitate optimisation of corticosteroid dose. It would also allow a diagnosis of severe asthma to be made without escalation of corticosteroid treatment past a point where, in many cases, there is unlikely to be any therapeutic benefit.

Patients with T2-high disease have refractory eosinophilic asthma where, despite adherence with high-dose inhaled corticosteroids, there is persistent type-2 cytokine-driven inflammation and airway eosinophilia. Currently, these patients frequently require systemic corticosteroids to improve disease control, but the therapeutic management of this group of patients with severe asthma will be transformed over the next decade with the advent of additional novel target-specific therapies targeting the T2-cytokine axis. Omalizumab is currently available in the clinic and is a recombinant DNA-derived humanised immunoglobulin (Ig) G1K monoclonal antibody that binds selectively to human IgE at the same site as the high-affinity IgE receptor, forming immune complexes with free IgE.32 This binding inhibits interaction of IgE with IgE receptors on the surface of mast cells, basophils and other cell types, preventing the release of inflammatory mediators that occurs in allergic asthma. Clinical trials have demonstrated reduced unscheduled emergency visits and hospital admissions, and current guidelines advocate the use of omalizumab as an add-on therapy in severe asthma.32

Many new biological therapies targeting T2-high disease will be available in the next five years and will generate many interesting questions, including differential efficacy between monoclonal antibodies targeting IL-5/receptor IL-5 (IL-5R) (mepolizumab, benralizumab, reslizumab), IL-13 (lebrikizumab, tralokinumab) and IL-4Rα (dupilumab). Other strategies targeting the T2 axis, including anti-Gr1Th2 and novel anti-IgE therapies (quirilizumab, MEDI-4212, ligelizumab), will also be targeting overlapping patient groups; identifying which patients respond better to different classes of drugs may require ‘head-to-head’ studies. Many of these new therapies will come to market with a companion diagnostic or predictive biomarker of clinical response, which is a current limitation of omalizumab.

Bronchial thermoplasty delivers radio-frequency energy to the airways with the aim of reducing airway smooth muscle mass and hyperresponsiveness,33 although its role in the management of severe asthma remains to be established, particularly with the advent of target-specific pharmacological therapies. A major currently unmet need in severe asthma is therapeutic management of T2-low/non-corticosteroid-responsive facets of severe asthma. It now seems clear that asthma symptoms and altered physiology are manifest in the absence of T2-cytokine/eosinophilic inflammation, but it is unclear what underlying pathophysiological mechanisms drive these processes. Possibilities include a different inflammatory process or non-inflammatory structural problems such as abnormal smooth muscle contractility, aberrant epithelial signalling or airway infection. Understanding the extent and mechanism of T2-low disease in severe asthma will be a major research focus in the next decade. The role of IL-17 in asthma has generated interest, and an initial study using anti-IL-17 (brodalumab) suggested some efficacy in asthma patients with significant bronchodilator reversibility,34 but the precise role of IL-17 in severe asthma needs to be established. Preliminary data using macrolide therapy in patients with low peripheral blood eosinophil counts have also suggested exacerbation reduction, but whether this is an antibacterial or other anti-inflammatory effect remains to be clarified.35 However, optimising corticosteroid treatment and the availability of novel target-specific treatments will provide a great opportunity to identify novel mechanisms in severe disease.

The primary focus of this programme is to target corticosteroid treatments more effectively, including widespread implementation of biomarker-based strategies to identify non-adherence and prevent inappropriate escalation of therapy. The programme will also examine a novel composite biomarker strategy to optimise corticosteroid therapy, which if successful will be easily transferred into routine clinical care. Future work will aim to understand why some patients and some aspects of the asthma syndrome do not respond to corticosteroids.

The greatest future challenge in severe asthma remains a ‘disease-modifying’ therapy. It is attractive to speculate that if we could understand why patients with a particular pattern
of disease (T2-high/eosinophilic), which is usually responsive to low doses of inhaled corticosteroids, becomes ‘relatively’ corticosteroid resistant and requires high-dose (often systemic) treatment, we could target this therapeutically. This area has been the subject of study for many years, but no precise mechanism, as evidenced by a proven therapeutic, has yet emerged. In a randomised controlled withdrawal study of omalizumab (the evaluating Xolair persistence of response after long-term therapy (XPORt) study), 176 patients who had been on omalizumab for at least five years were randomised to placebo or continuation of omalizumab.\(^{36}\) The placebo arm had a shorter time to first exacerbation than those who continued on omalizumab; however, notably, 47.7% of placebo patients had no exacerbation in a one-year follow-up period and it is interesting to speculate that some patients have a persistent benefit; however, further analysis and studies are required to determine whether this is the case. It is also worth noting that over 25% of those randomised were not on inhaled corticosteroids at the time of randomisation and it remains unclear whether these data can be extrapolated to patients with severe asthma on omalizumab who frequently require high-dose inhaled steroid treatment in addition to omalizumab to maintain disease control. However, what can be concluded is that, as a group, patients who withdraw omalizumab after long-term use do less well than those who continue treatment.

**Conclusion**

Severe asthma represents a significant unmet medical need. Novel therapeutics, targeting a particular severe asthma phenotype (T2-high/refractory eosinophilic), are arriving in the clinic and will substantially increase management options for this group. Precise clinical assessment, with a particular focus on adherence with inhaled steroid treatment, is critical to ensure that these therapies are used in the correct patient group. The arrival of these therapies will allow the research focus to shift towards understanding T2-low mechanisms in severe asthma.

**References**

34 Busse WW, Holgate S, Kerwin E et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 2013;188:1294–302.

Address for correspondence: Prof L Heaney, Centre for Infection and Immunity, Queen’s University of Belfast, Belfast City Hospital, Lisburn Road, Belfast BT9 7AB, UK. Email: l.heaney@qub.ac.uk